Washington: A new study has provided insight into glucagon's role in diabetic heart disease. The UT Southwestern-led study revealed the hormone glucagon's importance to the development of insulin ...

For the first time, scientists showed that targeting glucagon action in the brain may be a new frontier for regulating diabetes. For the first time, scientists at the Toronto General Research ...

An imbalance in the competing action of insulin and glucagon is widely viewed as a critical factor in onset of type 2 diabetes, a relentlessly increasing health problem. A delicate balance between two ...

New study reveals the importance of the hormone glucagon in the development of insulin resistance and cardiac dysfunction during Type 2 diabetes. The study from UT Southwestern presents opportunities ...

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

"This investigation found that inhibiting glucagon action has potent anti-diabetic effects. This treatment reduces the potent negative effects that fats have on tissues," said Dr. Philipp Scherer, ...

Researchers at UT Southwestern Medical Center report in a study that analyzing blood sugar regulatory actions of the specific hormone ghrelin may lead to the development of new diabetes treatments.

The actions of the structurally related proglucagon-derived peptides (PGDPs)—glucagon, glucagon-like peptide (GLP)-1 and GLP-2—are focused on complementary aspects of energy homeostasis. Glucagon ...

The glucose-lowering, insulin-sensitizing agent metformin works mainly by reducing gluconeogenesis and opposing glucagon-mediated signalling in the liver and, to a lesser extent, by increasing glucose ...

This is a preview. Log in through your library . Abstract Endoplasmic reticulum (ER) stress plays an important role in metabolic diseases like obesity and type 2 diabetes mellitus (T2DM), although the ...

Type 1 diabetes could be converted to an asymptomatic, non-insulin-dependent disorder by eliminating the actions of a specific hormone, new findings suggest. Type 1 diabetes could be converted to an ...

CAMBRIDGE, Mass., June 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today ...